🚀 Don’t miss out on our presentation at Swiss Biotech Day 2023! In just ⏳ 2 hours, we’ll be sharing the latest updates on our breakthrough macrophage-based immunotherapy for the treatment of solid tumors. Join us today at 16:15 – 16:30 in Room Rio, floor 2, to hear from Prof. Magdalena Król, CEO of Cellis.
Our clinical stage biotech company is developing Macrophage Drug Conjugates (MDCs), a promising new therapy for solid tumors, with a focus on glioblastoma, ovarian, and pancreatic cancer. Our preclinical results show the elimination of tumors or significant tumor shrinkage, and we’re preparing to progress our technology to the first in human clinical trials.
Visit our website, www.cellis.eu, to learn more about our company profile and get ready for an exciting presentation!
#clinicaltrials #technology #immunotherapy #macrophages #mdc
